Stockreport

Immuneering: Clinical Catalyst In January, Cash Raised For Phase 3 [Seeking Alpha]

Immuneering Corporation - Class A  (IMRX) 
PDF IMRX's near-term catalyst is the January 7, 2026, release of 12-month OS data from the phase 2a trial of atebimetinib in pancreatic cancer. With $227.6M in cash post- [Read more]